- Neuroderm's ND0612H and ND06121 were tested in Parkinson's disease patients and compared with standard of care, oral levodopa/carbidopa (LD/CD).
- ND06121 achieved levodopa plasma levels that could only be achieved through surgical intervention.
- When the news came out about Neuroderm's positive impact on Parkinson's disease patients, the stock price more than doubled, almost hitting the $20 per share, The Street reports. But it's fallen considerably since then, settling at about $13 per share as of press time Friday.
Many of the symptoms associated with Parkinson's disease (PD), including trembling and shuffling gait, are associated with reduced levels of dopamine. Because levodopa is a precursor to dopamine, one common therapy has been to continuously replace dopamine levels.
However, because levodopa has a half short-life and is rapidly metabolized, many patients undergo a surgical procedure to facilitate automated levodopa replacement. The advent of Neuroderm's new therapy may make it possible to achieve therapeutic levodopa levels without surgery.
The company's small-cap Nasdaq stock may be down compared to the initial heights it reached based on the data, but it's still solid, and Neuroderm's forecast is an overall positive.